Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has provided an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received marketing authorization from China’s National Medical Products Administration for tagitanlimab, a PD-L1-directed monoclonal antibody, in combination with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal cancer. This approval is based on positive results from a phase III clinical trial showing improved progression-free survival and objective response rates compared to standard chemotherapy, marking an important milestone in the company’s oncology portfolio.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative monoclonal antibodies. The company operates in the biotech industry, primarily targeting cancer treatment therapies.
YTD Price Performance: -0.43%
Average Trading Volume: 306,248
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$36.23B
See more data about 6990 stock on TipRanks’ Stock Analysis page.